Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced a U.S. government contract option exercise of approximately $54 million to deliver CNJ-016 (VIGIV) to ASPR for smallpox preparedness, plus $6.6 million in new international orders for ACAM2000. The release cites prior multi-year Canada agreements up to $140 million CAD with >$35 million CAD expected in 2026.

The orders cover licensed medical countermeasures and include U.S. FDA-approved indications and safety warnings for VIGIV and ACAM2000.

Positive

• $54M U.S. government option exercised for CNJ-016 (VIGIV)
• $6.6M incremental international ACAM2000 product orders
• Multi-year Canada agreements valued up to $140M CAD with >$35M CAD expected in 2026

Negative

• Myocarditis risk reported at 5.7 per 1,000 primary ACAM2000 vaccinees (95% CI: 1.9-13.3)
• Serious safety warnings and contraindications for VIGIV and ACAM2000 may limit use and uptake

News Market Reaction – EBS

-1.58%

5 alerts

-1.58% News Effect

+2.8% Peak in 6 hr 25 min

-$7M Valuation Impact

$435.88M Market Cap

0.1x Rel. Volume

On the day this news was published, EBS declined 1.58%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $435.88M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ASPR VIGIV contract: $54 million USD International ACAM2000 orders: $6.6 million USD Canada agreements max value: $140 million CAD +5 more

8 metrics

ASPR VIGIV contract $54 million USD Contract award value for VIGIV to ASPR

International ACAM2000 orders $6.6 million USD New incremental orders from international government partner

Canada agreements max value $140 million CAD Multi-year agreements with Government of Canada

Canada 2026 orders $35 million CAD More than this amount expected in 2026 orders

VIGIV concentration 5% Liquid Formulation of Vaccinia Immune Globulin Intravenous (Human)

Myocarditis rate 5.7 per 1000 Suspect myocarditis/pericarditis rate in primary ACAM2000 vaccinees

Myocarditis 95% CI lower 1.9 Lower bound of 95% CI per 1000 primary vaccinees

Myocarditis 95% CI upper 13.3 Upper bound of 95% CI per 1000 primary vaccinees

Market Reality Check

Price: $7.93 Vol: Volume 779,108 is below t...

low vol

$7.93 Last Close

Volume Volume 779,108 is below the 20-day average of 1,272,043 (relative volume 0.61x). low

Technical Price at $8.01 is trading below the 200-day MA of $9.39 and 43.03% under the 52-week high.

Peers on Argus

EBS slipped 0.5% while peers were mixed: KMDA up 0.43%, SIGA up 1.63%, and EOLS/...

1 Up

EBS slipped 0.5% while peers were mixed: KMDA up 0.43%, SIGA up 1.63%, and EOLS/ETON/CGC down between 1.02% and 3.91%. Only ORGO appeared on momentum scans, and sector momentum was limited.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Board appointment	Neutral	-0.8%	New director with extensive healthcare and financial leadership joins board committees.
Feb 26	Earnings results	Positive	-26.6%	Reported FY2025 net income and margin expansion with strong naloxone revenue.
Feb 26	Stock buyback	Positive	-26.6%	Announced new $50M repurchase program replacing prior authorization.
Feb 26	Govt contracts	Positive	-26.6%	Secured Canadian multiyear contracts up to CAD 140M for countermeasures.
Feb 12	FDA approval	Positive	-0.2%	FDA approved NARCAN® OTC multipacks for higher-volume distribution channels.

Pattern Detected

Recent history shows multiple ostensibly positive catalysts (contracts, FDA approval, buyback) followed by negative or flat 24-hour price reactions.

Recent Company History

Over the last few months, Emergent reported several notable developments. On Feb 12, 2026, it received U.S. FDA approval for OTC NARCAN® multipacks after distributing over 85 million doses historically. On Feb 26, it posted FY2025 revenue of $742.9M, net income of $52.6M, and announced a new $50M buyback alongside Canadian biodefense contracts worth up to CAD 140M. Despite these, the stock saw a -26.58% reaction on that date, contrasting with today’s additional government contract wins.

Market Pulse Summary

This announcement adds more than $60M in smallpox-related orders, including a $54M VIGIV contract wi...

Analysis

This announcement adds more than $60M in smallpox-related orders, including a $54M VIGIV contract with ASPR and $6.6M in ACAM2000™ purchases from an international partner, building on Canadian agreements up to CAD 140M. It underscores Emergent’s role in biodefense preparedness. Investors may track future contract visibility, execution on existing multi-year agreements, and how recurring government demand contributes to revenue stability versus prior periods.

Key Terms

vaccinia immune globulin intravenous (human), immune globulin (human), aseptic meningitis syndrome (ams), transfusion-related acute lung injury (trali), +4 more

8 terms

vaccinia immune globulin intravenous (human) medical

"CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration"

A human-derived antibody medicine given through a vein to treat serious complications from vaccinia (the virus used in smallpox vaccines) or related poxvirus exposures. Think of it as a concentrated pool of ready-made defenders that can be given to someone whose own immune system can’t fight the vaccine virus effectively; for investors, its importance lies in demand driven by vaccination campaigns, outbreak responses, stockpiling, regulatory approvals, and manufacturing or supply constraints.

immune globulin (human) medical

"VIGIV is an Immune Globulin (Human), 5% Liquid, indicated for the treatment"

A medicine made from donated human plasma that contains concentrated antibodies—proteins the body uses to fight infections and regulate immune reactions. It is used to replace missing antibodies or calm overactive immune responses, like sending a ready-made team of defenders into a weakened or confused immune system. Investors watch it because production depends on donor supply, manufacturing capacity and regulation, and it can be a steady revenue source but carries safety and reimbursement risks.

aseptic meningitis syndrome (ams) medical

"Aseptic meningitis syndrome (AMS)Noncardiogenic pulmonary edema"

Aseptic meningitis syndrome is inflammation of the thin membranes that cover the brain and spinal cord caused by non-bacterial triggers such as viruses, medications, or immune reactions, producing symptoms like headache, fever and neck stiffness. It matters to investors because reports of AMS can prompt safety reviews, clinical trial pauses, regulatory scrutiny or liability risk for health-care products—like a warning light that can slow or halt a company’s progress and affect valuation.

transfusion-related acute lung injury (trali) medical

"Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)]Transmission"

Transfusion-related acute lung injury (TRALI) is a rare but serious reaction that can occur within hours after a blood transfusion, causing sudden shortness of breath and fluid in the lungs that impairs oxygen delivery. It matters to investors because TRALI cases can trigger product recalls, tighter regulation, legal liability, and reputational damage for companies that collect, process or supply blood products, potentially leading to costly corrective actions and shifts in market demand.

stevens-johnson syndrome medical

"erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum"

A rare but serious medical condition where the skin and mucous membranes blister and peel away, similar to a severe burn that affects large areas of the body and often requires hospital care. For investors it matters because it is a known, sometimes drug-triggered safety issue that can halt clinical trials, prompt regulatory warnings or recalls, and lead to large legal and financial consequences for companies producing implicated medicines or devices.

myocarditis medical

"Warning: Serious ComplicationsMyocarditis and pericarditis (suspect cases observed"

Inflammation of the heart muscle that can weaken the heart’s ability to pump and cause symptoms such as chest pain, shortness of breath, or abnormal heart rhythms. Investors care because myocarditis can affect healthcare costs, clinical trial outcomes, regulatory decisions, product safety perceptions, workforce availability, or lead to legal and reputational risks for companies, similar to how a car engine problem can halt a business until it's fixed.

pericarditis medical

"Serious ComplicationsMyocarditis and pericarditis (suspect cases observed at a rate"

Pericarditis is inflammation of the thin sac that surrounds the heart, like irritation of a protective sleeve or a balloon around the organ. It can cause chest pain, fatigue and other symptoms and is important to investors because cases linked to a drug, vaccine or medical device can change regulatory decisions, affect sales and trigger safety reviews or legal risk, which can move a company’s stock and future outlook.

encephalomyelitis medical

"myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy"

Encephalomyelitis is inflammation of the brain and spinal cord that can be caused by infections, autoimmune reactions, or other triggers; think of it as swelling that disrupts the body’s central processing and wiring. It matters to investors because the condition can drive demand for diagnostics, treatments, and clinical trials, affect regulatory reviews and healthcare costs, and influence the valuation of companies developing relevant therapies or tests.

AI-generated analysis. Not financial advice.

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6 million USD. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent’s medical countermeasures portfolio and will support the partner’s smallpox biodefense strategy. These orders stem from a recurring international customer and demonstrate the importance of threat preparedness around the world.

“We are pleased to support both the U.S. government and a longstanding international partner with critical smallpox medical countermeasures that directly align with their national security and public health preparedness efforts,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Our strong track record of developing, manufacturing and supplying biodefense products to international governments reinforces the strength of our partnerships, particularly in light of the growing risk of biological threats globally.”

This announcement follows Emergent’s recent execution of multi-year agreements with the Government of Canada valued up to $140 million CAD to support the country’s biologic threat preparedness and response infrastructure, of which, more than $35 million CAD orders will be received in 2026.

U.S. FDA-Approved Indication and Select Important Safety Information for CNJ-016^® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV)

Indication
VIGIV is an Immune Globulin (Human), 5% Liquid, indicated for the treatment of complications due to vaccinia vaccination including eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, vaccinia infections in individuals who have skin conditions, and aberrant infections induced by vaccinia virus (except in cases of isolated keratitis). VIGIV is not indicated for postvaccinial encephalitis.  

Important Safety Information
Warning: Interactions with Glucose Monitoring Systems

Blood glucose measurement in patients receiving Vaccinia Immune Globulin Intravenous (Human) (VIGIV) must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. Maltose in IGIV products may give falsely high blood glucose levels in certain types of blood glucose testing systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings.

Contraindications: VIGIV is contraindicated in isolated vaccinia keratitis, individuals with a history of anaphylactic or severe systemic reaction to human globulins, and IgA-deficient patients with antibodies against IgA and a history of IgA hypersensitivity.

Warnings & Precautions:

• Hypersensitivity to human immune globulin (acute anaphylaxis)
• Acute renal dysfunction/failure
• Thrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity
• Hemolysis or hemolytic anemia
• Aseptic meningitis syndrome (AMS)
• Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)]
• Transmission of infectious agents from human plasma
• Monitor renal function and urine output in patients at risk of renal failure; check baseline blood viscosity in patients at risk of hyperviscosity; and conduct confirmatory tests if hemolysis or TRALI is suspected

Adverse Reactions: The adverse drug reactions to VIGIV treatment in clinical trials (>10%) include headache, nausea, rigors and dizziness.

To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or medicalinformation@ebsi.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for VIGIV for complete Boxed Warning and safety information.

U.S. FDA-Approved Indication and Select Important Safety Information for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Indication
ACAM2000® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.

Important Safety Information
Warning: Serious Complications
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000® or other live vaccinia virus vaccines that were used historically. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequelae and/or death.

Contraindications: Do not administer ACAM2000® to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.

Warnings & Precautions: Myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal vaccinia, fetal death, and accidental eye infection (ocular vaccinia) that may lead to blindness.

Adverse Reactions: Inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache.

To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.

Please see the full Prescribing Information for ACAM2000® for complete Boxed Warning and safety information.

About Emergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the availability and government procurement of CNJ-016^® and ACAM2000® are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

FAQ

What is the value of Emergent BioSolutions' March 25, 2026 U.S. contract award (EBS)?

Emergent secured approximately $54 million under an ASPR option exercise. According to the company, this funds delivery of CNJ-016 (VIGIV) for U.S. smallpox preparedness and stems from an existing 10-year contract.

How much are the new international orders for ACAM2000 reported by EBS on March 25, 2026?

Emergent reported new incremental international orders valued at $6.6 million. According to the company, these orders are for ACAM2000 and come from a recurring international government partner.

Do the March 2026 contracts include any other recent government agreements for EBS?

Yes. Emergent referenced multi-year agreements with Canada valued up to $140 million CAD, with more than $35 million CAD in orders expected in 2026. According to the company, these support national biologic threat preparedness.

What are the main safety concerns investors should note about ACAM2000 (EBS)?

ACAM2000 carries serious risks including myocarditis and pericarditis at a rate of 5.7 per 1,000 primary vaccinees. According to the company, additional boxed warnings and contraindications may affect usage and liability considerations.

What indication does CNJ-016 (VIGIV) have under FDA approval noted by Emergent?

VIGIV is indicated for treatment of complications from vaccinia vaccination, excluding postvaccinial encephalitis. According to the company, VIGIV treats conditions like eczema vaccinatum and progressive vaccinia.

How can suspected adverse reactions to EBS products be reported by healthcare providers?

Suspected adverse reactions can be reported to Emergent or regulatory bodies using provided contacts. According to the company, U.S. reporting includes FDA MedWatch and company medical information phone and email contacts listed in the prescribing information.